Martine Piccart, MD, PhD

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses biomarkers in early breast cancer.

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Martine J. Piccart, MD, PhD, professor of Oncology, Université Libre de Bruxelles, director of Medicine, Jules Bordet Institute, Brussels, Belgium, discusses the primary analysis of the prospective randomized MINDACT study, which evaluated the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the success of trastuzumab for the treatment of breast cancer.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an overview of the IMPAKT conference.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Martine Piccart, MD, PhD, discusses the implications of the HERA trial, which looked at two years compared with one year of trastuzumab after adjuvant chemotherapy in women with HER2-positive breast cancer.